Healthcare / Medical DevicesTaiwan
$24.30
-0.55 (-2.22%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-215.1M · quality 53.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-31.3%
↓Gross Margin
54.9%
↑Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.8%
FCF CAGR
—
FCF margin
-49.5%
FCF / Net income
1.17x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $475.2M · net income $-201.2M · FCF $-235.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $475.2M | $475.2M | $343.1M | $395.2M | $390.3M |
| Net Income | $-201.2M | $-201.2M | $-260.8M | $-164.2M | $-184.7M |
| EBITDA | $-143.2M | $-143.2M | $-197.9M | $-98.6M | $-125.4M |
| EPS | — | — | -2.88 | -2.01 | -2.14 |
| Gross Margin | 54.9% | 54.9% | 59.5% | 68.0% | 60.0% |
| Operating Margin | -46.9% | -46.9% | -80.9% | -47.2% | -49.3% |
| Net Margin | -42.3% | -42.3% | -76.0% | -41.6% | -47.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.09 | 0.09 | 0.02 | 0.05 | 0.06 |
| Current Ratio | 6.02 | 6.02 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-235.5M | $-235.5M | $-215.1M | $-211.5M | $123.7M |
| Returns | |||||
| ROE | -31.3% | -31.3% | -29.7% | -24.8% | -22.6% |
| Valuation | |||||
| P/B | 3.88 | 3.88 | 2.08 | 3.14 | 3.06 |
| Growth & Yield | |||||
| Revenue Growth | 38.5% | 38.5% | -13.2% | 1.2% | — |
| EPS Growth | — | — | -43.3% | 5.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+14.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.88 → n/d
Residual
+14.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.